Table 2.
The bactericidal activities of extracts from transgenic B. subtilis strains equivalent to the efficacious doses of antibiotic against different pathogens.
| Pathogens | Strains | |||
| C117 a | C166 a | T1 b | T13 b | |
| Promoter | ||||
| P43 | P43 | P43 | P43 | |
| Tandem repeats c | ||||
| 2× CiMAM | 2× CiMAM | 3× LFB | 3× LFB | |
| Plasmid copy number d | ||||
| 1057 | 349 | 931 | 647 | |
| S. epidermidis | 48 (Amp) | 41 (Amp) | 154 (Amp) | 130 (Amp) |
| E. tarda | 39 (Amp) | 37 (Amp) | 79 (Amp) | 33 (Amp) |
| V. parahaemolyticus | 47 (Tet) | 25 (Tet) | 30 (Tet) | 26 (Tet) |
| V. natriegens | 57 (Tet) | NA | NA | 9 (Tet) |
Unit: ng·L−1, a C117 and C166: the transgenic B. subtilis strains harbored pP43-2CiMAM-GFP expression vector used in this study; b T1 and T13: the transgenic B. subtilis strain harbored pP43-6LFB-GFP expression vector published by Lee et al., 2019; c tandem repeats of cDNA encoding CiMAM or LFB (2×: double-repeats; 3×: triple repeats) in the expression vector transmitted stably in the transgenic lines; d An average copy number of plasmids per cell; (Amp) expressed as an equivalent antibacterial potency against Ampicillin; (Tet) expressed as an equivalent antibacterial potency against Tetracycline.